Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Edesa Biotech stock
Learn how to easily invest in Edesa Biotech stock.
Edesa Biotech Inc is a biotechnology business based in the US. Edesa Biotech shares (EDSA) are listed on the NASDAQ and all prices are listed in US Dollars. Edesa Biotech employs 16 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Edesa Biotech
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EDSA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Edesa Biotech stock price (NASDAQ: EDSA)Use our graph to track the performance of EDSA stocks over time.
Edesa Biotech shares at a glance
|Latest market close||$4.87|
|52-week range||$4.15 - $12.00|
|50-day moving average||$6.08|
|200-day moving average||$6.04|
|Wall St. target price||$18.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.00|
Buy Edesa Biotech shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Edesa Biotech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Edesa Biotech price performance over time
|1 week (2022-01-10)||-10.15%|
|1 month (2021-12-17)||-14.71%|
|3 months (2021-10-19)||-40.75%|
|6 months (2021-07-19)||-6.70%|
|1 year (2021-01-19)||-4.32%|
|2 years (2020-01-17)||36.03%|
|3 years (2019-01-18)||327.19%|
|5 years (2017-01-19)||139.90%|
Edesa Biotech financials
|Gross profit TTM||$311,200|
|Return on assets TTM||-116.79%|
|Return on equity TTM||-120.39%|
|Market capitalisation||$71.1 million|
TTM: trailing 12 months
Edesa Biotech share dividends
We're not expecting Edesa Biotech to pay a dividend over the next 12 months.
Have Edesa Biotech's shares ever split?
Edesa Biotech's shares were split on a 1:6 basis on 9 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Edesa Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Edesa Biotech shares which in turn could have impacted Edesa Biotech's share price.
Edesa Biotech share price volatility
Over the last 12 months, Edesa Biotech's shares have ranged in value from as little as $4.15 up to $12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Edesa Biotech's is 1.2599. This would suggest that Edesa Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Edesa Biotech overview
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy
Frequently asked questionsWhat percentage of Edesa Biotech is owned by insiders or institutions?
Currently 27.934% of Edesa Biotech shares are held by insiders and 16.372% by institutions. How many people work for Edesa Biotech?
Latest data suggests 16 work at Edesa Biotech. When does the fiscal year end for Edesa Biotech?
Edesa Biotech's fiscal year ends in September. Where is Edesa Biotech based?
Edesa Biotech's address is: 100 Spy Court, Markham, ON, Canada, L3R 5H6 What is Edesa Biotech's ISIN number?
Edesa Biotech's international securities identification number is: CA27966L1085 What is Edesa Biotech's CUSIP number?
Edesa Biotech's Committee on Uniform Securities Identification Procedures number is: 27966L108
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert